# Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder

> **NCT02845323** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 15 (actual)

## Conditions studied

- Urothelial Carcinoma
- Bladder Cancer

## Interventions

- **DRUG:** Nivolumab in combination with Urelumab
- **DRUG:** Nivolumab monotherapy

## Key facts

- **NCT ID:** NCT02845323
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-05-16
- **Primary completion:** 2027-07-31
- **Final completion:** 2027-12
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2026-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02845323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02845323, "Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02845323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*